Alligator Bioscience AB reports financial results for Q1 2025 and provides a business update
24-month data from OPTIMIZE-1 show 29.4% survival rate for mitazalimab—three times higher than chemotherapy alone FDA alignment secure ...
Alligator Bioscience announces initiation of HLX22 Phase 2 trial in breast cancer by Shanghai Henlius Biotech, Inc.
Lund, Sweden – 23 April 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that Shanghai Henlius Biotech, Inc ...
Notice of annual general meeting in Alligator Bioscience AB
The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the annual general meeting to be held on Wednesday 7 May 2 ...
Alligator Bioscience determines record date for reverse share split of ordinary shares and reminds of the recalculation of warrants
The board of directors of Alligator Bioscience AB (“Alligator Bioscience” or the “Company”) has resolved that the re ...
Change in number of shares and votes in Alligator Bioscience AB
During March 2025, the number of shares and votes in Alligator Bioscience AB (“Alligator Bioscience”) has increased as a result ...
Alligator Bioscience publishes Annual Report for 2024
Lund, Sweden, 27 March 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2024, as well ...
Bulletin from the extraordinary general meeting in Alligator Bioscience AB
Today, on 27 March 2025, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows ...
Alligator Bioscience announces leadership transition in clinical development
Lund, Sweden – 21 March 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that Dr. Sumeet Ambarkhane MD, Chi ...
Alligator Bioscience Announces FDA Orphan Drug Designation for HLX22/AC101 in Gastric Cancer
Lund, Sweden – 20 March 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the U.S. Food and Drug Admini ...